This contrasts with the poor specificity of EZH2 for carcinoma versus B3 thymoma in our study, and may relate to sampling bias (given the use of tissue microarrays in the prior study) and the use of different antibodies (clone 6A10 from Novocastra used by Kim et al. [4] versus clone D2C9 from Cell Signaling Technology, used in our study). Here, EZH2 is linked to thymoma.